Amai Proteins' Revolutionary Sweelin®: Confirming Safety and Efficacy for Healthier Sweetening
In an exciting development in the food science industry, Amai Proteins has announced the first successful clinical trial results for its innovative sweet protein, sweelin®. This study was recently published in the esteemed journal, Food Chemistry, a significant milestone that not only validates sweelin® but also sets a new standard in the field of sweeteners.
A First of Its Kind Clinical Study
This unique double-blind, randomized crossover clinical trial aimed to thoroughly assess the metabolic effects of sweelin® compared to traditional sweeteners like stevia and dextrose. The results were overwhelmingly positive, indicating that sweelin® does not impact blood glucose, insulin, or GLP-1 levels in healthy adults. Conducted at the Clinical Research Center of Tel Aviv Sourasky Medical Center under strict Good Clinical Practice (GCP) standards, the trial involved participants consuming beverages sweetened with sweelin® matched for sweetness equivalency to 75 grams of glucose. Over a period of 120 minutes, researchers meticulously monitored blood glucose and hormone levels.
Significance of the Findings
The absence of adverse outcomes during the study is a major victory for Amai Proteins. All participants completed the trial without any dropouts or negative side effects related to the test item. Such evidence strengthens confindence in sweelin® as a viable alternative sweetener for consumers aiming to reduce their sugar intake without sacrificing taste. As Dr. Amir Guttman, CEO of Amai Proteins, emphasizes, the company undertook this study not merely out of regulatory requirements, but to enhance consumer confidence in sweelin®'s safety and health profile.
The implications of this research extend beyond just individual health. With growing public awareness about sugar's impact on health, sweelin® presents a revolutionary solution. This next-generation sweet protein not only offers sugar reduction but also upholds the necessary sweetness consumers enjoy. As such, it allows food manufacturers to innovate healthier products that meet the rising demand for reduced-sugar alternatives.
Validation by Food Chemistry
Being featured in Food Chemistry, which has an impressive impact factor of 9.8, underscores the importance of this research. The journal is recognized for its contributions to advancing scientific knowledge in food science and nutrition, making it an ideal platform for Amai Proteins' results. This publication solidifies sweelin®’s place in the competitive sweetener landscape, enabling faster market adoption and increasing commercial interest from food and beverage customers in the U.S.
Regulatory Milestones
The study is complemented by Amai Proteins' recent achievements, having received GRAS (Generally Recognized As Safe) approval from the FDA and approval as a food additive from the Singapore Food Agency earlier this year. These approvals mark substantial progress in validating not only the safety and effectiveness of sweelin® but also its regulatory readiness, thus enhancing its commercial viability and laying the groundwork for entry into new markets.
The Future of Sweet Protein
Amai Proteins is committed to developing, scaling, and commercializing sweet proteins for the food, beverage, and dietary supplement industries through advanced food technology and precision fermentation. With sweelin®—an innovative protein derived from the serendipity berry—offering sweetness approximately 3,000 times that of sugar, it holds great promise for a healthier future in food formulations.
The ability to achieve significant sugar reductions without compromising taste positions sweelin® as a game-changer both for consumers and producers. As awareness grows about the dangers of excessive sugar consumption, solutions like sweelin® could drastically reshape diet patterns while enabling healthier choices that do not sacrifice enjoyment.
For more insights into Amai Proteins and its revolutionary products, visit
Amai Proteins and stay tuned for the latest developments in sweet protein technology.